• One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion
• Lexaria solves this problem with its DehydraTECH(TM) drug delivery technology
• Since the company began working on this technology back in 2014, it has made major strides in the delivery of hypertension and anti-viral treatments

Since its inception, Lexaria Bioscience (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules in drugs. With its drug delivery technology, DehydraTECH(TM), the company has aided in developing hypertension and anti-viral treatments (https://ibn.fm/96k7t). This is a big achievement for the company and is already making an impact in the pharmaceutical industry. One of the main challenges with drug delivery and the overall effectiveness of the drugs is first-pass metabolism/excretion. Also referred to as the first-pass effect or presystemic metabolism, this is an occurrence where whenever a patient takes a drug orally, it enters the liver and suffers extensive biotransformation to a level where its bioavailability or overall effectiveness is drastically reduced, ultimately showing subtherapeutic action (https://ibn.fm/vfEfN). In the past, scientists and pharmaceutical companies have tried to address this by calculating the total quantity of the metabolized drug, with an equivalent amount of excess drug added to the oral formulation. Alternatively, they have tried to explore alternative routes of drug administration, specifically designed to bypass first-pass metabolism. Of the tried and tested workarounds to the issue, some have shown more promise than others. However, nothing comes close to Lexaria’s DehydraTECH. Since Lexaria began working on this technology in 2014, DehydraTECH has developed considerably and impacted the industry. So far, it has proven useful for potentially treating hypertension, along with the delivery of Colchicine, a drug with known SARS-CoV-2 anti-viral properties (https://ibn.fm/eaBrv). DehydraTECH is applied by incorporating an intermediate step in the formulation and manufacturing of existing or orally ingestible and topical products. This is a crucial step that entails mixing the active ingredients as a delivery “payload” with specific fatty acids and infusing the mixture into a substrate material. The next step involves using a controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into end-product production across various dosage form factors. From a commercial standpoint, Lexaria’s technology is proving to offer an additional layer that companies that offer consumer supplements, prescription, and non-prescription-based drugs, cannabis, and nicotine products can use to improve the effectiveness of both new and existing products. With over 50 pending patents in countries worldwide, along with 21 granted patents in countries of highest commercial potential such as the US, the EU, Japan and more, Lexaria understands the value of this technology and its usefulness, both to patients and pharmaceutical companies. Gone are the days of having to calculate the total quantity of the metabolized drug once orally taken. DehydraTECH allows the body to bypass first-pass-liver processing, allowing for smaller doses and effective treatment for specific conditions and ailments. It is a tremendous milestone, not just for Lexaria but also for the medical industry. With what the company has achieved since 2014, it is evident that bigger and better things are to come. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• EMR report projects that North America is likely to be fastest, largest marketplace for cannabis beverages
• Cannabis beverage industry projected to grow at CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026
• BevCanna manufactures its own beverage product lines, offers white-label services to companies looking for the highest-quality products available

North America will be a leader in the global cannabis beverage market, according to a recent Expert Market Research (“EMR”) report (https://ibn.fm/ucsAZ). This projection bodes well for BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products company developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. “North America is likely to be the fastest and largest marketplace for cannabis beverages,” the EMR report stated. “The legalization of cannabis for medical, therapeutic, and recreational purposes is driving the growth of market. In 2018, Canada legalized the utilization of marijuana for recreational and medical purposes. Various states in the United States have made the addition of cannabis infusion legal in food and beverages. This factor is predicted to spice up the expansion of the cannabis food and beverage market in North America.” EMR went on to note that worldwide, the cannabis beverage industry is expected to grow at a CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026. The report noted that increasing demand for wellness beverages is expected to drive the expansion of cannabis beverages industry. Other drivers behind the market growth include the lower sugar content of the product, the presence of consistently dosed amount of cannabis for consumption, the legalization of marijuana consumption for medical and recreational purposes in many countries, and the growing consumer interest in cannabis edibles. “Cannabis consumers are shifting their interest from smoking cannabis to other ways, like beverages, tinctures, and chocolates, and other edibles,” the report noted. “Consumers are willing to consume concentrated and cannabis-infused products, which successively is anticipated to support the market growth. Cannabis beverages are predicted to exchange other marijuana-infused consumables, like chocolates, cookies, brownies, and confectionaries like gummies and candies which are considered to be not healthy. This factor is predicted to spice up the demand for cannabis drinks over the forecasted period.” Ideally situated in this booming space, BevCanna is in a position to leverage its state-of-the-art facilities and expertise to manufacture its own beverage product lines and to provide white label solutions to a growing list of third-party companies. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• 5,900 hospitals in the US lack the necessary extensive EEG tech
• BRSF has created a cost-effective solution capable of supplying these hospitals with the equipment needed and broadening the reach of each neurologist
• Emergency departments and hospitals are not the only markets in need of brain monitoring devices, and the industry is expected to grow to $208 billion by 2023

For most U.S. patients, an EEG is mostly unavailable during their journey, from home by EMS to the Emergency department. Additionally, for those patients who are admitted to the ICU, less than 45 percent of ICUs offer EEG monitoring. There are approximately 6,090 hospitals in the U.S., and around 5,900 of them lack the necessary extensive EEG tech coverage. There are several reasons for the lack of access:

• Costs and/or space: 70% of US hospitals do not have the equipment for routine EEGs
• Traditional EEGs require a specialized technician to administer and read the data
• The equipment is bulky, which restricts accessibility and mobility
• Twenty (20) states have less than 10 neurologists per 10,000 patients
• Neurological care needs are increasing with the aging population

Brain Scientific (OTCQB: BRSF) has created a solution that makes EEG technology accessible. The Company’s neurotech ecosystem is making it possible for all hospitals to perform EEG tests efficiently. The technology is simple to use. Neurologists are given the resources necessary to automate the tedious tasks and focus their energy on the patient while simultaneously broadening their range of impact. BRSF’s ecosystem begins with the disposable and easy-to-apply clinical-grade NeuroCap(TM), patented and FDA-cleared, that comes in small, medium, large, and pediatric (extra small) sizes. This disposable headset comes equipped with 22 pre-gelled electrodes that eliminate the task of head measurement and electrode placement. This significantly reduces the amount of time needed to set up, limiting the amount of contact between the patient and the medical professional applying the headset. In addition, because it is disposable and does not need to be painstakingly cleaned before moving on to the next patient, more EEGs can be administered, and the risk of cross-infection is significantly reduced. The NeuroEEG(TM), patented and FDA cleared, is a portable and wireless EEG amplifier that fits into the palm of your hand and is used to monitor electrical brain activity. By making EEG technology more available, BRSF has created a time-saving and cost-effective solution for hospitals while simultaneously meeting the growing need for additional neurological care of the communities those hospitals serve. Emergency departments and hospitals are not the only markets that require brain monitoring devices. Improved technology is necessary in specialized niche markets that address Alzheimer’s disease, traumatic brain injury, depression, epilepsy, ADHD, stroke, sleep disorders, dementia, migraine, and more. It’s estimated that the U.S. medical device industry will grow to $208 billion by 2023, and BRSF is ready to meet that increasing need. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Up to 70% of all medical decisions are based on lab tests. These tests cost between 3% and 6% of total patient-care costs
• The average patient spends about $260 on lab tests, a figure that is mainly associated with waiting for test results
• With point-of-care (“POC”) testing, waiting time can improve by as much as 46 minutes per patient, thus making it cheaper for the patient
• Avricore understands this problem, hence its investment in point-of-care technologies designed to make disease diagnosis easier, affordable, and more efficient

Over the past few decades, disease diagnosis has proven to be the single most important ongoing development in medicine, and for a good reason. The surge in infectious diseases has shown the importance of rapid and accurate diagnosis. Cases of Ebola outbreaks, along with the recent Covid-19 pandemic, have shown the significance of proper diagnosis and, even more importantly, point-of-care (“POC”) testing (https://ibn.fm/gzafZ). Early and accurate diagnosis has proven to improve the overall effectiveness of treatments while also helping the infected patient avoid long-term complications. Additionally, misdiagnosed or undiagnosed patients can unknowingly transmit the disease they have to others. In other cases, inaccurate diagnosis has led to the misuse or overuse of antibiotics, ultimately resulting in antibiotic resistance. Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a Canadian-based enterprise, since its inception, has maintained its primary focus on developing a network of point-of-care analyzers, offering advanced technologies that aid with easy, fast, and efficient diagnosis. This health diagnostics technology innovator utilizes its HealthTab(TM) platform in community pharmacies, rural areas, and workplaces, thereby cutting down on the time it takes for a patient to get a proper diagnosis and medication for their ailment (https://ibn.fm/mcwMV). As it currently stands, up to 70% of all medical decisions are based on lab tests. Typically, these tests account for between 3% and 6% of total patient-care costs, which can be significant if a patient requires multiple tests or if the initial test proves unforthcoming (https://ibn.fm/UKtMz). Avricore understands that this is an issue, so it has invested a lot in rapid testing for patients. So far, the company, through its partners, offers rapid diagnosis for diabetes and cardiovascular conditions, and even Covid-19 (https://ibn.fm/w6u9p). POC testing has proven to offer the highest cost savings, which can then be traced down to the decreased cost of waiting for results. With rapid turnaround times, patients can save between 8-20% of lab costs. For instance, in the United States, patients spend as much as $260 each on lab tests and costs associated with waiting for their results. With POC testing, as Avricore is currently offering, waiting can improve by as much as 46 minutes per patient, resulting in monetary savings. For further context, the use of a diagnostic test for early detection of Methicillin-Resistant Staphylococcus Aureus (“MRSA”) allowed doctors to prescribe optimum antibiotics 1.7 days sooner, thereby reducing the length of hospital stays by 6.2 days and lowering hospital costs by over $21,000. Researchers also pointed out during the Ebola crisis that had POC tests been used during the epidemic, its scale could have been reduced by over a third. Avricore understands the importance of proper and efficient disease diagnosis, hence its investment in point-of-care analyzers. The company has made incredible strides over the past few years, forming critical partnerships with pharmacies and bringing its services closer to the people. This has proven useful in the company’s onsite testing and reporting capabilities for SARS-CoV-2, RSV, Influenza A & B and Strep (https://ibn.fm/7zO7d). Referring to itself as a total health innovator, Avricore is constantly seeking to capitalize on technological advancement and consumer health trends, thereby offering consumers, health providers, and life-science companies the ability to control spending and health outcomes (https://ibn.fm/yHMLr). Going forward, the company intends to become the world’s largest health diagnostics company. It is currently focusing on point-of-care technologies within community pharmacies to achieve this. According to the company, doing so will make the diagnosis and overall healthcare more accessible and affordable to the masses. What the company is doing is transforming disease diagnosis and laying the foundation for what is to come in the future. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• The company gains the client base offered by Walmart while still maintaining control over inventory, pricing, fulfillment, and customer care
• Available brands will include Oatly, Nature’s Path, Made in Nature, and Simply Organic
• Since 2020, PlantX has offered many services through the company’s platform, including access to over 5,000 plant-based or vegan items across its vast catalogue
• PlantX shows dedication to consumers by offering a platform full of plant-based products, meal delivery programs, a plant delivery program, and even forums where like-minded consumers can interact

Dedicated to being the digital face of the plant-based community, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is providing consumers with a one-stop shop for all things plant-based. Quickly growing and evolving through the company’s catalog of verticals, PlantX offers more than 5,000 plant-based products to consumers across North America. Now, the company also launched as a seller on the Walmart Marketplace in the United States, where it will have over 500 plant-based grocery items available, ranging in variety and brands, including Oatly, Nature’s Path, Made in Nature, and Simply Organic. Having access to Walmart’s marketplace ecosystem is a big opportunity for PlantX, and it should ultimately help the company position itself as a leader in the plant-based industry. “The decision to apply and launch as a Seller on Walmart’s US Marketplace was inspired by PlantX’s experience as a Seller on the Walmart Marketplace in Canada, where PlantX has launched over 900 distinct plant-based items since June,” PlantX CEO Lorne Rapkin explained the decision (https://ibn.fm/KrJCF). “The new agreement will enable PlantX to integrate its growing selection of plant-based products onto the Walmart platform in the U.S. and have access to Walmart’s extensive customer network and digital marketing resources while maintaining full control over our inventory, pricing, fulfillment, and customer care.” As a high-growth technology company that focuses on consumer-packaged-goods (“CPG”) for plant-based opportunities, the PlantX platform is a community that includes:

• Plant-based grocery and pantry items, including vitamins, cosmetics, and even pet food
• Meal delivery with recipes created by well-known plant-based chefs worldwide
• A plant shop that delivers a wide variety of affordable indoor houseplants to homes across the United States and Canada
• Easy to follow plant-based recipes weekly
• Partnerships with restaurants, nutritionists, chefs, and brands
• A community of like-minded individuals

Since its launch in February 2020, PlantX has offered a variety of services through the comprehensive platform. The online marketplace features over 5,000 items across all of its product categories. The digital interface provided by PlantX spans an initiative for health and wellness, having been compared to the likes of Amazon. The platform provides consumers with the ability to fulfill a plant-based life at the click of a button. PlantX allows customers to shop, find recipes, read blogs, be a part of a community, use an educational interface, view cosmetics, read corporate updates, subscribe to the company newsletter, and more. To date, PlantX has launched multiple verticals under its brand. These include new meals and programs by renowned chefs, flagship PlantX locations, PlantX branded goods, U.S. meal delivery and LIV, and online peer-to-peer fitness. Using a consumer-friendly interface, the PlantX website makes it easy to navigate and find what is needed. Forums are available for consumers to communicate with one another, swap recipes, locate restaurants, and more. In the future, PlantX plans to continue scaling through organic growth, strategic partnerships, and accretive M&A opportunities. The company intends to expand with a global strategy for distribution in North America, Europe, and Israel. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• UUUU’s San Juan County Clean Energy Foundation designed to assist communities surrounding Energy Fuels’ White Mesa Mill in southeastern Utah
• Company initially donating $1 million, plans to donate annual funding equal to 1% of the mill’s future revenues
• Investing back into the San Juan County community will give company opportunity to support, catalyze sustainable economic and community development

Committed to being a strong member of the community, Energy Fuels (NYSE American: UUUU) (TSX: EFR)  has established the San Juan County Clean Energy Foundation (https://ibn.fm/y7aW1). The foundation is a fund created to contribute to the communities surrounding Energy Fuels’ White Mesa Mill in southeastern Utah. Energy Fuels kicked off the fund by depositing $1 million into the foundation, noting that the company plans to continue to donate annual funding equal to 1% of the mill’s future revenues. The funds from the foundation are earmarked to support the local economy and local priorities, specifically focusing on supporting education, the environment, health/wellness, and economic advancement in the city of Blanding, San Juan County, the White Mesa Ute Community, the Navajo Nation and other area communities. “The communities that surround our facility deserve to share in the benefits of the mill’s clean-energy future,” said Energy Fuels CEO Mark Chalmers. “We see San Juan County as becoming a critical minerals hub for the U.S., and we believe the foundation is truly the best way to make an impact and difference in the lives of those who work alongside us as we pursue these goals.” In the announcement, Chalmers noted that uranium, which is the fuel for carbon-free, emission-free baseload nuclear power, is one of the cleanest forms of energy in the world. “The rare earths we are now producing are used for the manufacture of permanent magnets for electric vehicles, wind turbines and other clean energy and modern technologies, and the thorium and other radioisotopes we are evaluating for recovery from our rare earth and uranium processing streams have the potential to provide the isotopes needed for emerging targeted alpha therapy cancer-fighting therapeutics. The very heart of our business — uranium and rare-earth production and recycling — helps us play a big part in addressing global climate change, reducing air pollution, and making the world a cleaner and healthier place.” “The processing of rare earths at the White Mesa Mill, in addition to processing and recycling uranium, is one of the best opportunities I have seen in my entire 40+ year career, as electric vehicles, renewable energy systems, and other clean energy and advanced technologies drive demand,” Chalmers continued. “And the potential to also extract isotopes that can be used to fight cancer is a very important added opportunity. Investing back into the San Juan County community will give us the opportunity to help support and catalyze sustainable economic and community development, beyond good jobs and more tax revenues.” Local community leaders reacted to the announcement, with Blanding mayor Joe B. Lyman noting that the company has long been a major contributor to not only the employment base of the community but also for the well-being and prosperity of this region. “Over the last year, the company has met with local community members to understand and identify needs in the area,” he observed. “The formation of the foundation is a culmination of these efforts and the beginning of a long-term commitment to improve the quality of life for everyone in the San Juan County area to help us reach our full potential.” While Blanding only boasts a population of a little more than 3,000, the city is the largest one in San Juan County. Resources in the area include mineral processing, mining, agriculture, local commerce, tourism and transportation. In addition, the community serves as a gateway to nearby natural, cultural and archaeological resources. Energy Fuels noted that the foundation will have a community-based advisory board, which will assist in determining the best allocation for the funds. This will “ensure that the foundation’s contributions are well planned and correspond to the specific needs and aspirations of the communities,” the company stated. Energy Fuels is a leading U.S.-based uranium mining company, supplying U₃O₈ to major nuclear utilities. Energy Fuels also produces vanadium from certain projects, as market conditions warrant, as well as rare earth carbonate. With corporate offices in Lakewood, Colorado, near Denver, and all of its assets and employees in the United States, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• The company completed the acquisition of LQwD Financial Corp. in June 2021
• LQwD FinTech has purchased over C$3 million worth of bitcoin at an average price of C$46,000 (US$36,800)
• LQwD FinTech investors gain exposure to bitcoin as an asset
• Investors also gain exposure to the Lightning Network, which is positioned for rapid growth

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption. LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network. The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin. LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network. The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent. Product The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale. Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future. The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe. Market Outlook Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025. Management Team Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017. Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller. Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus. For more information, visit the company’s website at https://lqwdfintech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• The initial campaign is designed to help deliver the company’s brand messaging to artists and fans worldwide
• The company is using the brand awareness foundation to build additional campaigns digitally, on social media, and for advertising purposes
• The new version of the Fan Pass platform offers artists the resources needed to expand their musical offering on a more professional level

Friendable (OTC: FDBL), a mobile technology and marketing company focused on providing artists with a platform to share their music and fans a place to find their favorite artists, all in one place, has kicked off the first phase of a brand awareness campaign for its Fan Pass artist streaming platform. In the first phase, the company has released 15- and 30-second radio spots on Spotify and other programmatic networks (https://ibn.fm/ME45t). These radio spots are a part of the 120-day plan put together by the company, which included the release of version 2.0 of the platform. Their goal is to deliver the company’s brand messaging to artists and global fans and music lovers who are constantly on the lookout for new artists and music. “Following the release of our all-new version 2.0 of the Fan Pass platform, we have now taken the necessary steps to ensure our platform is stable, our service offerings are sound, and the support tools are in place to provide a superior experience for both artists and fans,” Friendable CEO Robert A. Rositano Jr. commented about the radio ads. “Now, it’s time to begin promoting our brand and mission with the release of these two radio spots, which are just beginning to run on various networks, including Spotify.” The radio spots are only the beginning of the company’s digital campaign. Having the foundation of brand awareness comes before the specific and direct artist or fan acquisition campaigns as a part of the overall strategy. Rositano finds that it is more impactful to the company, to begin with, some “spot-driven” messaging coming behind the initial direct digital media, social media influencer, and general advertising campaigns to target the fan acquisition and artist signups. Also in the works is a public relations outreach strategy to enhance the multi-phase approach of making Fan Pass a household name. Fan Pass is providing a live-streaming platform that thousands of artists, independent and more established, have signed up for since its inception. Friendable commenced its 120-day plan with the release of Fan Pass platform version 2.0 in July 2021 – exactly one year from its initial release. Additionally, the company released a new mobile app which was approved by Google Play and Apple Stores for download. Besides being a live music streaming platform, Fan Pass offers artists various resources that allow them to advance in their art. Artists can take advantage of the Pro Services offered on the Fan Pass platform to help build their brand, attract more fans, and earn income as musicians with the quality branding resources needed. Categories available on the Pro Services page include Artist/Band Logo Design, Merch Design, and Marketing Materials. These range in pricing from $45 for a social ad/ announcement design to promote the next three events all the way to a $400 pro merch collection with five high-resolution designs placed on any five merch items available. Streaming gear is also available for artists (at all levels) on the Fan Pass platform. Artists can purchase new streaming equipment, create their events, or purchase replacement lighting – the opportunities and resources are endless for artists coming to the platform. Pricing for the items begins at $9.95 and up, offering artists a music-centered place to access some of the best gadgets to fine-tune their craft. Friendable intends to continue making more options available to artists and fans as its 120-day plan draws closer to completion. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes
• The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan
• Tryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit
• The company expects to initiate Phase 2a trials to begin before the end of the year for treating certain eating disorders, with Phase 2b trials to follow next year

Novel pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) continues to garner attention for its development of psilocybin as potential treatments for medical conditions with largely unmet needs, presenting an overview of its business and ongoing clinical trials for its two trademarked drug candidates most recently at the Oppenheimer Fall Healthcare Summit. Tryp is nearing the launch of a Phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (PWS), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction. The company also plans to execute Phase 2b clinical trials for its proprietary psychedelic candidate TRP-8803 to evaluate its ability to penetrate the natural blood-brain barrier and effectively alleviate pain and addiction concerns, including targets for phantom limb pain and fibromyalgia. Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit featured companies’ presentations and one-on-one meetings by invitation only through a virtual platform online. Tryp joined other select public companies in the sector for a presentation that paired investors with management teams to discuss key programs in detail, delivering its address on Sept. 21 (https://ibn.fm/30YVm). The management team also presented an overview of the company the prior week at the H.C. Wainwright 23rd Annual Global Investment Conference and at the Canaccord Genuity Virtual Growth Conference last month. “I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida,” Tryp Chairman and CEO Greg McKee stated in July (https://ibn.fm/P8zw8). “The next six months represent an important stage in development for us as we initiate multiple Phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders.” Tryp’s product development moves beyond the initial interests in testing psychedelics for treating solely mental health issues such as depression, anxiety, addiction, and PTSD, combining supervised administration of the drug with psychotherapy in response to select medical conditions in which specific neurological maladies play a causal role. Tryp also is distinguishing itself by developing a novel method of administration for its TRP-8803 candidate to make the experience better for patients, leading to a provisional patent to protect the unique features of the proprietary formulation. The company’s drug products are manufactured in the United States as part of an exclusive supply chain for its active ingredients that assures Tryp will have sufficient quantities to complete its clinical trials and establish eventual commercialization. Tryp expects Phase 2a trials for the eating disorders and for phantom limb pain to begin before the end of the year (https://ibn.fm/finBj). For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• SGMD anticipates using the licenses for three new vertically integrated Nug Avenue cannabis delivery hubs
• Each of the licenses can be used for up to three of five categories of licensed cannabis-related business activities
• Definitive agreement aligns with announcement that Sugarmade has acquired LA property for first of new Nug Avenue cannabis delivery hubs

In its continued focus on building is cannabis delivery interests, Sugarmade (OTC: SGMD) has signed a definitive agreement to obtain three nonstorefront California cannabis licenses from the Los Angeles Department of Cannabis Regulation (“DCR”), along with corresponding licenses from the California Bureau of Cannabis Control (“BCC”) (https://ibn.fm/EyI3W). SGMD is focused on establishing itself as a leader in California’s vertically integrated cannabis marketplace, and the company anticipates using the licenses for its planned three new vertically integrated Nug Avenue cannabis delivery hubs. “Once we have put all of these new licenses to use, we will have quadrupled our distribution footprint in the world’s largest cannabis market,” said Sugarmade CEO Jimmy Chan. “We also continue to move toward establishing our own cultivation operations. Together, these steps are part of our core vision – to establish a full farm-to-door vertically integrated cannabis company capable of driving a much greater percentage of total sales to the bottom line for our shareholders, while capturing much greater control over product quality for our customers.” According to the announcement, each of the three licenses that SGMD plans to acquire can be used for up to three of the five categories of licensed cannabis-related business activities allowed under the terms of these licenses: retail delivery, manufacturing, distribution, transport-only, and cultivation. The company noted that by using each license for a combination of retail delivery of cannabis products with supply chain distribution of cannabis products and manufacturing/packaging of cannabis products, it will possess the required licensing to open three new Nug Avenue locations; the company plans on opening the new operations in the Los Angeles metropolitan area. The signing of the definitive agreement aligns ideally with the company’s announcement that it has acquired a property in Los Angeles that will serve as the first of these new Nug Avenue cannabis delivery hubs. SGMD’s initial involvement in Nug Avenue came as a result of an agreement announced in February, in which the company acquired a 70% stake in the Lynwood, California, operations of Nug Avenue. Based on the agreement, SGMD will recognize 100% of revenue and 70% profits generated from Nug Avenue’s Lynwood delivery service operations. In addition. Those same terms will carry over to each new Nug Avenue location as the company expands. Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes Nug Avenue, CarryOutsupplies.com, SugarRush(TM) and Lemon Glow. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD